Clarendon Fund Managers
Clarendon Fund Managers Limited is a venture capital firm based in Belfast, Ireland, established in 2001. The firm specializes in investing in small and medium enterprises, primarily within the manufacturing and tradable services sectors. It focuses on companies located in Northern Ireland and typically makes initial investments ranging from £20,000 to £250,000, with the potential for follow-on financing. Clarendon manages £42.5 million in regional venture capital funds, including a £30 million Co-Investment Fund, and has invested in over 60 companies to date. The firm aims to exit its investments within five to seven years, often co-investing alongside business angels and private investors.
See.Sense creates award-winning products that make riders safer on the road, and technology that generates the data cities need to build better transport infrastructure. Our products are used by more than 50,000 cyclists worldwide and we're the official bike light and ride insights suppliers to both British Cycling and Cycling Ireland. The data our patented products gather is unique - seeing us work with leading smart cities around the world, to improve cycling infrastructure, reduce congestion and improve mobility in cities. We've won multiple business, design and innovation awards, and design and manufacture our technology products in Northern Ireland.
See.Sense creates award-winning products that make riders safer on the road, and technology that generates the data cities need to build better transport infrastructure. Our products are used by more than 50,000 cyclists worldwide and we're the official bike light and ride insights suppliers to both British Cycling and Cycling Ireland. The data our patented products gather is unique - seeing us work with leading smart cities around the world, to improve cycling infrastructure, reduce congestion and improve mobility in cities. We've won multiple business, design and innovation awards, and design and manufacture our technology products in Northern Ireland.
Non Equity Assistance in 2014
Autism Biotech develops biochemical test for the early reliable diagnosis of autism. Autism Biotech's product, ASDtect, a diagnostic test for early and reliable detection of autism spectrum disorder. Based on two fully owned and granted patents for peptide biomarkers for autism, ASDtect targets a huge and untapped market. The company is currently conducting trials and aims to make ASDtect available in the near future. Autism Biotech is headquartered in Belfast, Northern Ireland.
PathXL, a Northern Ireland-based leader in digital pathology image analysis, workflow software and educational tools. PathXL’s image analysis and tissue pathology software will complement Philips’ Digital Pathology Solutions offering, and help expand the business’ leadership in this fast-growing field. Pathology involves the examination of patient tissue samples and plays a crucial role in the diagnosis and treatment of a wide variety of diseases, including cancer.
Kelsius is the supplier of automation technology for product safety and compliance to the food services and healthcare industries. Using the wireless temperature monitoring technology, digital HACCP Management system, and cloud based data hosting and processing, Kelsius systems improve product safety, ensure regulatory compliance, and optimize costs associated with these activities. Kelsius was founded 2003 and is headquartered in Donegal, Ireland